Viking Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Viking Therapeutics, Inc. Overview

Viking Therapeutics is a clinical-stage biopharmaceutical company developing innovative therapies for metabolic and endocrine disorders, with a focus on obesity and fatty liver disease. The company's flagship asset VK2735, a dual GLP-1/GIP receptor agonist, demonstrated impressive Phase 2 data showing up to 14.7% weight loss and is advancing into Phase 3 registrational trials.

Strategic Profile

Viking positions itself as a potential challenger to the obesity treatment duopoly, leveraging its metabolic expertise and a strong balance sheet ($706 million in cash) to maintain operational independence while pursuing high-value licensing partnerships for supporting programs like VK2809. The company operates a lean biotech model focused on IP advancement and clinical progression toward FDA approval and commercialization.

Competitive Landscape

Viking competes in the rapidly growing obesity therapeutic market dominated by Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound), which hold significant first-mover advantages. Viking's differentiation rests on VK2735's potency and dual mechanism, positioning it for potential market share capture as the obesity market expands toward $100 billion addressable market with room for multiple winners.

Industry Context

Viking Therapeutics, Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development - Metabolic Disorders and Obesity Therapeutics.

Key facts

Headquarters: San Diego, US · Revenue: $0 · Market cap: $3.8B